Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for...

Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs...

Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding...

The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical...

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.

The pharmaceutical industry is increasingly focused on the development of specialized drug products with new treatment modalities, including previously undruggable...

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.